Wednesday, February 19, 2014

America's Fastest-Growing Drug Problem

America's Fastest-Growing Drug Problem

The American people want a miracle pill that they can just pop into their mouth to knock out disease (which will NEVER happen). The American people want this because a miracle pill would allow them to keep living lavishly and frivolously while eating their beloved degenerate, denatured and devalued Standard American Diet.

No pill will ever knock out (cure) any disease. A single pill didn't cause the pathology. It was the thought process (mindset), diet and lifestyle (or death style) of the person that caused the pathology. And yes, consuming various or multiple pills (drugs) plays a role in the development of pathology. Disease is multidimensional and not one-dimensional. Unfortunately for Western allopathic medicine, they treat disease in a one dimensional way.

Drugs become personalities in new marketing push
Big Pharma is starting to give a personality to its drugs in order to push revenues towards its annual sales target of $1.3 trillion by 2018.

Personality traits such as dependable, optimistic and elegant are being used to encourage people to want a specific drug.

Much of this new marketing spin is happening in the US where direct-to-consumer advertising is permitted. It’s hoped that consumers will then ask the doctor to prescribe the ‘dependable’ drug.

Fifteen well-known drugs, such as Viagra, Lipitor and Prozac, are being given ‘brand personalities,’ say researchers from the John Molson business school, a technique that has been used for years by Apple, Coca-Cola and other major manufacturers.

The personalities have two aspects: competence and innovation. So as well as being dependable, drugs are also being promoted as unique and original. This new marketing strategy is a necessary next step for Big Pharma as it moves towards global annual sales of $1.3 trillion by 2018 in the face of stiff competition from generics and tough regulation. (Source: Journal of Consumer Marketing, 2013; 30: 583)


No comments: